Share this article
Share this article
SAN FRANCISCO, March 3, 2021 /PRNewswire/ Blue Note Therapeutics, Inc., today announced the closing of a Series A financing round of $26.25 million. Proceeds will allow the company to scale the organization and fund near-term clinical trials of its lead prescription digital therapeutic (PDT), which will potentially improve the treatment of cancer. The capital will also support the development of Blue Note s pipeline assets. The Series A financing was led by JAZZ Venture Partners and joined by Summer VC.
Blue Note Therapeutics is dedicated to serving patients suffering from cancer-related distress. Working closely with leading cancer research centers and patient communities, Blue Note is developing clinically validated medical devices designed to improve overall cancer outcomes. These products will help address the specific psychosocial needs of oncology patients and may reduce comorbidities such as anxiety, depression, and fear of cancer re
New ASH Guidelines: VTE Prevention, Treatment in Cancer Patients
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Utilizing Pharmacogenomics Information to Guide AML Treatment
pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.
DGAP-News: Molecular Health GmbH: Molecular Health and FALCO biosystems team up to provide genetic analysis services using MH Guide/BRCA and MH Guide/Mendel
PMS2, respectively. Therefore, testing
BRCA1/2 genes and other heritable cancer-associated genes is becoming increasingly important: both to evaluate the affected patient s individual risk of developing cancer
[1],[2], and as a predictive biomarker and companion diagnostic test for certain drugs
[3]. Whereas MH Guide/BRCA detects variants in HBOC-associated genes, MH Guide/Mendel can analyze large gene panels as well as whole-exome or whole-genome data, so that many different hereditary diseases can be identified at once. With this collaboration in place, Japanese patients will benefit from state-of-the-art genetic identification of inherited diseases like Hereditary Breast and Ovarian Cancer and many other diseases. This will allow sooner diagnosis and potentially earlier therapeutic intervention , said Christian Meisel,